When and how to treat essential thrombocythemia

New England Journal of Medicine

Volumn 353, Issue 1, 2005, Pages 85-86

  Tiziano Barbui, M D ^a   Finazzi, Guido ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; QUINAZOLINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; BLEEDING; BONE MARROW; BONE MARROW SUPPRESSION; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIABETES MELLITUS; DYSLIPIDEMIA; EDITORIAL; ERYTHROCYTE; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LEUKEMIA; LEUKOCYTE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK FACTOR; SMOKING; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; DRUG COMBINATION; NOTE;

ANTINEOPLASTIC AGENTS; ASPIRIN; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOCYTIC, ACUTE; MYELOFIBROSIS; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 21444457418     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058093     Document Type: Editorial

References (15)

1. Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211-9.
2. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-32.
3. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-62.
4. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
5. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76.
6. Harrison CN, Campbell PJ, Buck G, et al. A randomized comparison of hydroxyurea with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
7. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-6.
8. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24.
9. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118:786-90.
10. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 2000;85:1126-34.
11. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-70.
12. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
13. James C, Ugo V, Le Couedic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005;434:1144-8.
14. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
15. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.